Myasthenia Gravis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myasthenia Gravis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2015', provides an overview of the Myasthenia Gravis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myasthenia Gravis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myasthenia Gravis Overview 8
Therapeutics Development 9
Pipeline Products for Myasthenia Gravis - Overview 9
Pipeline Products for Myasthenia Gravis - Comparative Analysis 10
Myasthenia Gravis - Therapeutics under Development by Companies 11
Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 13
Myasthenia Gravis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Myasthenia Gravis - Products under Development by Companies 17
Myasthenia Gravis - Products under Investigation by Universities/Institutes 18
Myasthenia Gravis - Companies Involved in Therapeutics Development 19
Alexion Pharmaceuticals, Inc. 19
Alnylam Pharmaceuticals, Inc. 20
Astellas Pharma Inc. 21
Biokine Therapeutics Ltd. 22
CuraVac, Inc. 23
Cytokinetics, Inc. 24
GlaxoSmithKline plc 25
Grifols, S.A. 26
HanAll Biopharma Co., Ltd. 27
Neurotune AG 28
Pfizer Inc. 29
Regenesance BV 30
Toleranzia AB 31
Myasthenia Gravis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ALN-CC5 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BKT-130 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CK-2066260 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
eculizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GL-2045 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HL-161 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
immune globulin (human) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NT-1654 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein for Myasthenia Gravis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Regenemab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tacrolimus - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
tirasemtiv - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Vaccine for Myasthenia Gravis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine for Myasthenia Gravis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Myasthenia Gravis - Recent Pipeline Updates 69
Myasthenia Gravis - Dormant Projects 85
Myasthenia Gravis - Discontinued Products 86
Myasthenia Gravis - Product Development Milestones 87
Featured News & Press Releases 87
Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 87
Sep 16, 2014: Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 88
Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 89
Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 90
Jun 09, 2014: Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 90
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 92
Apr 24, 2014: Toleranzia supported by VINNOVA 93
Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 93
Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases 96
Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Tables
Number of Products under Development for Myasthenia Gravis, H1 2015 9
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 19
Myasthenia Gravis - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 20
Myasthenia Gravis - Pipeline by Astellas Pharma Inc., H1 2015 21
Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H1 2015 22
Myasthenia Gravis - Pipeline by CuraVac, Inc., H1 2015 23
Myasthenia Gravis - Pipeline by Cytokinetics, Inc., H1 2015 24
Myasthenia Gravis - Pipeline by GlaxoSmithKline plc, H1 2015 25
Myasthenia Gravis - Pipeline by Grifols, S.A., H1 2015 26
Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 27
Myasthenia Gravis - Pipeline by Neurotune AG, H1 2015 28
Myasthenia Gravis - Pipeline by Pfizer Inc., H1 2015 29
Myasthenia Gravis - Pipeline by Regenesance BV, H1 2015 30
Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H1 2015 69
Myasthenia Gravis - Dormant Projects, H1 2015 85
Myasthenia Gravis - Discontinued Products, H1 2015 86